OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 16, 2021
The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.
June 03, 2021
In addition to ADCs, other types of highly potent biologics require specialized manufacturing skills.
December 08, 2020
The company will expand its micronization abilities for highly potent drug compounds through this investment.
December 03, 2020
Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.
May 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?
March 02, 2020
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.
October 02, 2019
Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.
August 15, 2019
The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.
August 02, 2019
Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.
June 17, 2019
Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.